A Study to Evaluate Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and/or Refractory Multiple Myeloma
Clinical trial NCT06163898 · TERMINATED
Trial details
- NCT number
- NCT06163898
- Sponsor
- Celgene
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2024-02-27
- Primary completion
- 2025-06-03
- Enrollment
- 4
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.